Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: Design and rationale of the ROADMAP clinical trial

Joseph G. Rogers, Andrew J. Boyle, John B. O'Connell, Douglas A. Horstmanshof, Donald C. Haas, Mark S. Slaughter, Soon J. Park, David J. Farrar, Randall C. Starling

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. Objective The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. Methods This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. Clinical context This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.

Original languageEnglish (US)
Pages (from-to)205-210.e20
JournalAmerican Heart Journal
Volume169
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Heart-Assist Devices
Heart Failure
Clinical Trials
Therapeutics
Assisted Circulation
Cardiogenic Shock
United States Food and Drug Administration
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients : Design and rationale of the ROADMAP clinical trial. / Rogers, Joseph G.; Boyle, Andrew J.; O'Connell, John B.; Horstmanshof, Douglas A.; Haas, Donald C.; Slaughter, Mark S.; Park, Soon J.; Farrar, David J.; Starling, Randall C.

In: American Heart Journal, Vol. 169, No. 2, 01.02.2015, p. 205-210.e20.

Research output: Contribution to journalArticle

Rogers, Joseph G. ; Boyle, Andrew J. ; O'Connell, John B. ; Horstmanshof, Douglas A. ; Haas, Donald C. ; Slaughter, Mark S. ; Park, Soon J. ; Farrar, David J. ; Starling, Randall C. / Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients : Design and rationale of the ROADMAP clinical trial. In: American Heart Journal. 2015 ; Vol. 169, No. 2. pp. 205-210.e20.
@article{c9e7ebf4e09440cf8660ae935d9834d8,
title = "Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: Design and rationale of the ROADMAP clinical trial",
abstract = "Background Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. Objective The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. Methods This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. Clinical context This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in {"}stable{"} patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.",
author = "Rogers, {Joseph G.} and Boyle, {Andrew J.} and O'Connell, {John B.} and Horstmanshof, {Douglas A.} and Haas, {Donald C.} and Slaughter, {Mark S.} and Park, {Soon J.} and Farrar, {David J.} and Starling, {Randall C.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.ahj.2014.11.004",
language = "English (US)",
volume = "169",
pages = "205--210.e20",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients

T2 - Design and rationale of the ROADMAP clinical trial

AU - Rogers, Joseph G.

AU - Boyle, Andrew J.

AU - O'Connell, John B.

AU - Horstmanshof, Douglas A.

AU - Haas, Donald C.

AU - Slaughter, Mark S.

AU - Park, Soon J.

AU - Farrar, David J.

AU - Starling, Randall C.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. Objective The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. Methods This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. Clinical context This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.

AB - Background Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. Objective The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. Methods This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. Clinical context This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.

UR - http://www.scopus.com/inward/record.url?scp=84921719997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921719997&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2014.11.004

DO - 10.1016/j.ahj.2014.11.004

M3 - Article

C2 - 25641529

AN - SCOPUS:84921719997

VL - 169

SP - 205-210.e20

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -